Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients. BMC Nephrol 2017;18(1):219.
. .
.
Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Mol Cell Endocrinol 2014;394(1-2):13-20.
. Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. Mol Cell Endocrinol 2011;331(1):136-42.
. .
TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clin Sci (Lond) 2012;123(9):547-55.
. TRAIL shows potential cardioprotective activity. Invest New Drugs 2012;30(3):1257-60.
.